Allelic frequency of PON1 Q192R, CYP2C19*2 and CYP2C19*17 among Jordanian patients taking clopidogrel

被引:5
|
作者
Rjoub, Malek [1 ]
Saleh, Akram [2 ]
Hakooz, Nancy [3 ]
Imraish, Amer [4 ]
Jarrar, Yazun [5 ]
Zihlif, Malek [1 ]
机构
[1] Univ Jordan, Fac Med, Dept Pharmacol, Amman, Jordan
[2] Univ Jordan, Dept Internal Med, Univ Jordan Hosp, Amman, Jordan
[3] Univ Jordan, Dept Biopharmaceut & Clin Pharm, Fac Pharm, Amman, Jordan
[4] Univ Jordan, Dept Biol, Fac Sci, Amman, Jordan
[5] AlZaytoonah Univ Jordan, Coll Pharm, Dept Pharm, Amman, Jordan
关键词
CYP2C9; polymorphisms; Clopidogrel; Genotype; Allele frequency; PON1; genes; GENETIC-POLYMORPHISM; GENOTYPE FREQUENCIES; CYP2C19; PHARMACOGENETICS; PARAOXONASE-1; PHENOTYPE; VARIANT; 2C19;
D O I
10.4314/tjpr.v17i11.24
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To investigate the influence of allelic frequencies of PON1 Q192R, CYP2C19*2 and CYP2C19*17 genetic polymorphisms on the response to clopidogrel among Jordanian patients. Methods: Polymorphisms in CYP2C19 were assessed among 148 patients using PCR-RFLP assay. Results: The CYP2C19*2, CYP2C19*17, and PON1 Q192R allele frequencies were 9.8, 28.72 and 28.7 %, respectively. On the genotyping side, the frequencies of CYP2C19*1/1* and CYP2C19*1/2* were 80.4 and 19.6 %, respectively, but none of the patients had CYP2C19*2/2* genotype. The genotype frequencies CYP2C19*17 were 47.97, 46.62 and 5.41 % for wild-type C-C, heterozygote C-T, and the mutant T-T, respectively. PON1 genotype was 42.7 % for QQ, and 57.8 % for QR. None of the patients had RR genotype. Conclusion: Relative to other populations, the observed allelic frequencies are consistent with the values reported for Caucasian and Middle Eastern populations.
引用
收藏
页码:2275 / 2280
页数:6
相关论文
共 50 条
  • [21] Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
    Li-Wan-Po, Alain
    Girard, Thierry
    Farndon, Peter
    Cooley, Candy
    Lithgow, James
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (03) : 222 - 230
  • [22] Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population
    Hanioka, N.
    Tsuneto, Y.
    Saito, Y.
    Sumada, T.
    Maekawa, K.
    Saito, K.
    Sawada, J.
    Narimatsu, S.
    XENOBIOTICA, 2007, 37 (04) : 342 - 355
  • [23] Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients
    Rehman, Kashif Ur
    Akhtar, Tanveer
    Sabar, Muhammad Farooq
    Tariq, Muhammad Akram
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 10 (01) : 309 - 315
  • [24] A synergic effect between CYP2C19∗2, CYP2C19∗3 loss-of-function and CYP2C19∗17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients
    Hassani Idrissi H.
    Hmimech W.
    Khorb N.E.
    Akoudad H.
    Habbal R.
    Nadifi S.
    BMC Research Notes, 11 (1)
  • [25] The CYP2C19*17 variant is not independently associated with clopidogrel response
    Lewis, J. P.
    Stephens, S. H.
    Horenstein, R. B.
    O'Connell, J. R.
    Ryan, K.
    Peer, C. J.
    Figg, W. D.
    Spencer, S. D.
    Pacanowski, M. A.
    Mitchell, B. D.
    Shuldiner, A. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (09) : 1640 - 1646
  • [26] In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24
    Lau, Pui Shen
    Leong, Kenny Voon Gah
    Ong, Chin Eng
    Dong, Amelia Nathania Hui Min
    Pan, Yan
    BIOCHEMICAL GENETICS, 2017, 55 (01) : 48 - 62
  • [27] In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24
    Pui Shen Lau
    Kenny Voon Gah Leong
    Chin Eng Ong
    Amelia Nathania Hui Min Dong
    Yan Pan
    Biochemical Genetics, 2017, 55 : 48 - 62
  • [28] Frequency of CYP2C19 Polymorphism in Ischemic Patients
    Shawky, A.
    PUBLIC HEALTH GENOMICS, 2018, 21 : 15 - 15
  • [29] CYP2C19 Genotype and Outcomes of Clopidogrel Treatment
    Geisler, Tobias
    Bigalke, Boris
    Schwab, Matthias
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (05): : 481 - 481
  • [30] The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway
    Ford, Neville F.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (12): : 1474 - 1483